Endo Health price target raised to $86 from $75 at Goldman Goldman raised Endo Health's price target to $86 from $75 and updated estimates to incorporate the Boca deal closing and the divestiture of Healthtronics. Shares are Buy rated.
Endo rallies amid talk of conference cancellation Shares of Endo International are rallying 2% amid talk the company cancelled out of Leerink's conference next week. Endo has no events listed on its website and Bloomberg just reported that according to sources, the company cancelled its appearance at the conference. Shares of Endo are up $1.25 to $55.40 in afternoon trading.